N-(3-hydroxymethyl-β-carboline-1-yl-ethyl-2-yl)-L-Phe: development toward a nanoscaled antitumor drug capable of treating complicated thrombosis and inflammation

N-(3-hydroxymethyl-β-carboline-1-yl-ethyl-2-yl)-L-Phe: development toward a nanoscaled antitumor drug capable of treating complicated thrombosis and inflammation

Jianhui Wu,1–4 Ming Zhao,1–5 Yuji Wang,1–4 Yaonan Wang,1–4 Haimei Zhu,1–4 Shurui Zhao,1–4 Lin Gui,1–4 Xiaoyi Zhang,1–4 Shiqi Peng1–4 1Beijing Area Major Laboratory of Peptide and Small Molecular Drugs, 2Engine...

Full description

Bibliographic Details
Main Authors: Wu JH, Zhao M, Wang YJ, Wang YN, Zhu HM, Zhao SR, Gui L, Zhang XY, Peng SQ
Format: Article
Language:English
Published: Dove Medical Press 2017-01-01
Series:Drug Design, Development and Therapy
Subjects:
P-selectin
anti-tumor
anti-thrombosis
anti-inflammation
nanomedicine.
Online Access:https://www.dovepress.com/n-3-hydroxymethyl-beta-carboline-1-yl-ethyl-2-yl-l-phe-development-tow-peer-reviewed-article-DDDT

Internet

https://www.dovepress.com/n-3-hydroxymethyl-beta-carboline-1-yl-ethyl-2-yl-l-phe-development-tow-peer-reviewed-article-DDDT

Similar Items